Fisiopatología de la Inmunidad Innata

Publicaciones

  • Current Drug Targets

    01/01/2019

    Current pharmaceutical biotechnology

    Low Doses of CPS49 and Flavopiridol Combination as Potential Treatment for Advanced Prostate Cancer

    Zalazar F, Luca P, Gardner K, Figg WD, Meiss R, Spallanzani RG, Vallecorsa P, Elguero B, Cotignola J, Vazquez E, Siervi A.

  • Frontiers in Oncology

    22/06/2018

    Frontiers in Immunology

    Primary Immunodeficiencies Unravel the Role of IL-2/CD25/STAT5b in Human Natural Killer Cell Maturation

    Caldirola MS, Rodríguez Broggi MG, Gaillard MI, Bezrodnik L, Zwirner NW.

  • Journal of Immunology

    01/02/2018

    Journal of Immunology

    Human M2 Macrophages Limit NK Cell Effector Functions through Secretion of TGF-β and Engagement of CD85j

    Nuñez SY, Ziblat A, Secchiari F, Torres NI, Sierra JM, Raffo Iraolagoitia XL, Araya RE, Domaica CI, Fuertes MB, Zwirner NW.

  • Frontiers in Oncology

    17/01/2018

    Frontiers in Immunology

    Interleukin (IL)-23 Stimulates IFN-γ Secretion by CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells Activation

    Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI, Sierra JM, Secchiari F, Domaica CI, Fuertes MB, Zwirner NW.

  • 01/03/2017

    Molecular Cancer Research

    Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC

    Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL.

  • Frontiers in Oncology

    19/01/2017

    Frontiers in Immunology

    Regulation of NK Cell Activation and Effector Functions by the IL-12 Family of Cytokines: The Case of IL-27

    Zwirner NW, Ziblat A.